The 7-day contraceptive hormone-free interval should be consigned to history

被引:13
作者
MacGregor, E. Anne [1 ,2 ]
Guillebaud, John [3 ]
机构
[1] Barts Hlth NHS Trust, London, England
[2] Barts & London Queen Marys Sch Med & Dent, Ctr Neurosci & Trauma, London, England
[3] UCL EGA Inst Womens Hlth, London, England
关键词
COMBINED ORAL-CONTRACEPTIVES; PILL-FREE INTERVAL; ETHINYL ESTRADIOL; OPEN-LABEL; WOMEN; CYCLE; PHARMACOKINETICS; REGIMENS; SUPPRESSION; ADHERENCE;
D O I
10.1136/bmjsrh-2017-200036
中图分类号
D669 [社会生活与社会问题]; C913 [社会生活与社会问题];
学科分类号
1204 ;
摘要
Aim This review summarises the available data on the disadvantages of the 7-day contraceptive-free interval (CFI) of combined oral contraceptives (COCs), in contrast to shorter CFIs or continuous use - including flexible regimens - and provides recommendations for practice. Methods Relevant papers were identified by Medline and PubMed. The final reference list was generated on the basis of relevance to the review, with priority given to systematic reviews and randomised controlled trials. Results There is considerable inter-and intra-individual variation in the absorption and metabolism of COCs. Even with perfect use, the loss of endocrine suppression during the standard 7-day CFI allows follicular development with the risk of escape ovulation in a vulnerable minority. This risk increases in typical users whenever the CFI is prolonged: late restarts are a common reason for pill omissions. Shortening or eliminating the CFI improves contraceptive efficacy using the lowest doses available, without evidence to date of compromised safety. Conclusions There is no scientific evidence to support a 7-day CFI and it should be replaced either by a continuous flexible regimen, or extended regimens with a shortened CFI, prescribed first-line. In women preferring a monthly 'bleed', a 4-day CFI similarly provides a greater safety margin when pills are omitted.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 50 条
  • [1] Counselling to include tailored use of combined oral contraception in clinical practice: an evaluation
    Akintomide, Hannat
    Rank, Katherine Margaret
    Brima, Nataliya
    McGregor, Fiona
    Stephenson, Judith
    [J]. BMJ SEXUAL & REPRODUCTIVE HEALTH, 2018, 44 (01) : 36 - 41
  • [2] A multicenter, randomized study of an extended cycle oral contraceptive
    Anderson, FD
    Hait, H
    [J]. CONTRACEPTION, 2003, 68 (02) : 89 - 96
  • [3] [Anonymous], COCHRANE DATABASE SY
  • [4] [Anonymous], 2013, COCHRANE DB SYST REV
  • [5] Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives
    Archer, David F.
    [J]. CONTRACEPTION, 2006, 74 (05) : 359 - 366
  • [6] The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives
    Aubeny, E
    Buhler, M
    Colau, JC
    Vicaut, E
    Zadikian, M
    Childs, M
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2004, 9 (04) : 267 - 277
  • [7] Oral contraception: patterns of non-compliance. The Coraliance study
    Aubeny, E
    Buhler, M
    Colau, JC
    Vicaut, E
    Zadikian, M
    Childs, M
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2002, 7 (03) : 155 - 161
  • [8] INVESTIGATION OF THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN USING RADIOIMMUNOASSAY
    BACK, DJ
    BRECKENRIDGE, AM
    CRAWFORD, FE
    MACIVER, M
    ORME, MLE
    ROWE, PH
    WATTS, MJ
    [J]. CONTRACEPTION, 1979, 20 (03) : 263 - 273
  • [9] Baerwald Angela R, 2004, J Obstet Gynaecol Can, V26, P19
  • [10] An observational study of adherence to combined oral contraceptive regimens
    Bastianelli, Carlo
    Farris, Manuela
    Vecchio, Roberta Costanza Bruno
    Rosato, Elena
    Guida, Maurizio
    Benagiano, Giuseppe
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (02) : 168 - 172